FarrowSure B (Canada)This page contains information on FarrowSure B for veterinary use.
The information provided typically includes the following:
- FarrowSure B Indications
- Warnings and cautions for FarrowSure B
- Direction and dosage information for FarrowSure B
FarrowSure BThis treatment applies to the following species:
Erysipelothrix Rhusiopathiae-Leptospira Bratislava-Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
For use in swine only
PRODUCT DESCRIPTION: FarrowSure B is for vaccination of healthy breeding swine as an aid in preventing reproductive failure caused by porcine parvovirus (PPV), erysipelas caused by Erysipelothrix rhusiopathiae, and leptospirosis caused by Leptospira bratislava, L. canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. FarrowSure B is a liquid preparation of inactivated PPV, grown in an established porcine cell line; whole cultures of E. rhusiopathiae; and the six Leptospira serovars identified above. The vaccine is combined with a sterile adjuvant to enhance the immune response.
DISEASE DESCRIPTION: PPV and Leptospira are common agents of reproductive loss in swine. While infection with any of these pathogens may produce subclinical disease, infection by PPV during pregnancy may result in fetal resorption, stillbirths, and fetal mummification. Infection by Leptospira during the second half of pregnancy may cause stillbirths or abortions; late-term abortions are the most important economic effect of leptospirosis. Leptospirosis caused by any of the serovars represented here cannot be clinically differentiated. Abortions may also occur in sows infected with E. rhusiopathiae during pregnancy.
SAFETY AND EFFICACY: Safety of vaccine fractions in FarrowSure B was demonstrated in breeding-age swine. No significant postvaccination reactions were reported.
Efficacy of the fractions of FarrowSure B was demonstrated in challenge-of-immunity and immunogenicity tests. After challenge with virulent E. rhusiopathiae, vaccinated pigs remained clinically normal while nonvaccinated control pigs developed clinical disease. Studies conducted to assess immunologic interference based on antibody titers to PPV and all 6 Leptospira serovars showed no significant immunologic interference occurred between vaccine fractions.
L. bratislava is fastidious in its growth requirements and has proven difficult to isolate. However, L. bratislava has been isolated in aborted pigs and fetuses in European studies; and in 1986, Ellis and Thiermann reported the isolation of L. bratislava from the kidney and genital tract of 2 sows in the United States.1,2 Subsequently, L. bratislava was also isolated in the United States from weak pigs, stillborn pigs, and swine placental tissues.3,4 Recent serological surveys show that infections of swine by L. bratislava are prevalent. Antibody to L. bratislava, detectable by the microscopic agglutination test (MAT), has been shown to be present in sera from greater than 30% of finishing pigs and 50% of adult pigs.5,6 Furthermore, controlled vaccination studies conducted in swine herds showing evidence of infection and poor reproductive performance support the conclusion that L. bratislava can be controlled through vaccination.6
Challenge-of-immunity tests were conducted by scientists at the Veterinary Research Laboratories, Belfast, Northern Ireland to determine the efficacy of the L. bratislava fraction of FarrowSure B against virulent isolates of L. bratislava. Fifteen pigs were divided into 2 groups. Ten pigs were administered 2 doses of the L. bratislava bacterin in 2-mL doses given 2 weeks apart, and a group of 5 pigs was used as nonvaccinated controls. Subsequently, all pigs were challenged with virulent strains of L. bratislava. After challenge, L. bratislava was recovered from the kidneys of all 5 control pigs and from the oviduct of one of them. In contrast, leptospires were not recovered from the kidneys or genital tracts of the 10 vaccinated pigs. Leptospiraemia was demonstrated in the blood of all 5 control pigs beginning on the third postchallenge day. Leptospiraemia was demonstrated in only 2 of the 10 vaccinated pigs on the third postchallenge day. Two controls also experienced a rise in rectal temperature after challenge.
These results are similar to results of previously conducted challenge-of-immunity tests on the other 5 Leptospira fractions of FarrowSure B. In those studies also, vaccinated animals remained healthy after challenge, while nonvaccinated animals developed clinical signs of leptospirosis.
Directions For Use
1. General Directions: Shake well. Aseptically administer 5 mL intramuscularly.
2. Primary Vaccination: Administer a single 5-mL dose to healthy sows 14-60 days before breeding. Healthy gilts, however, should receive a single 5-mL dose as near as possible to 14 days before breeding. If gilts are vaccinated sooner, persisting maternal antibodies may interfere with vaccination. Healthy boars should receive a single 5-mL dose at least 14 days prior to introduction to the breeding herd. For protection against leptospirosis, a single dose of BratiVac®-6 is recommended either 3-6 weeks before or 3-6 weeks after administration of FarrowSure B.
3. Revaccination: Revaccination with a single dose is recommended before breeding. Boars should be revaccinated semiannually.
4. Good animal husbandry and herd health management practices should be employed.
1. Store at 2°-7°C. Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine.
4. Do not vaccinate within 21 days before slaughter.
5. Contains gentamicin as preservative.
6. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
7. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.
1. Ellis WA, McParland PJ, Bryson DG, et al: Leptospires in pig urogenital tracts and fetuses. Vet Rec 117:66-67, 1985.
2. Ellis WA, McParland PJ, Bryson DG, et al: Isolation of Leptospires from the genital tract and kidneys of aborted sows. Vet Rec 118:294-295, 1986.
3. Ellis WA, Thiermann AB: Isolation of Leptospira interrogans serovar bratislava from sows in Iowa. Am J Vet Res 47:1458-1460, 1986.
4. Bolin C, Cassells J: Isolation of Leptospira interrogans serovar bratislava from stillborn and weak neonatal pigs in Iowa. JAVMA 196:1601-1604, 1990.
5. Hanson LE: Role of Leptospira bratislava to leptospirosis in swine, Proceedings, American Association of Swine Practitioners. pp. 85-91, 1987.
6. Frantz JC, Hanson LE, Brown AL: Effect of vaccination with a bacterin containing Leptospira interrogans serovar bratislava on the breeding performance of swine herds. Am J Vet Res 50:1044-1047, 1989.
Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).
For veterinary use only
U.S. Veterinary License No. 190
Zoetis Inc., Kalamazoo, MI 49007, USA
Presentation: 10 doses (50 mL).
NAC No.: 1198050.3
16,740 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9H 4M7
|Technical Services Canada:||800-461-0917|
|Technical Services USA:||800-366-5288|
|Every effort has been made to ensure the accuracy of the FarrowSure B information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-02-06